Publication | Closed Access

Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group

Malignant DiseaseMedicineMelanomaPathologyPhase Ii StudyMalignant MelanomaCancer TreatmentOncologyRadiation OncologyCancer ResearchTumor Biopsy Study